|
16 Feb 2021 |
AstraZeneca COVID-19 vaccine authorised for emergency use by the World Health Organization
|
|
12 Feb 2021 |
ImmunityBio and NantKwest Announce FDA Authorization to Study hAd5 T-Cell COVID-19 Vaccine for Combination of Subcutaneous, Oral and Sublingual Boost to Induce T-Cell, Mucosal, and Antibody Immunity
|
|
12 Feb 2021 |
CureVac Initiates Rolling Submission With European Medicines Agency for COVID-19 Vaccine Candidate, CVnCoV
|
|
10 Feb 2021 |
AstraZeneca and IDT Biologika sign letter of intent to increase COVID-19 vaccine manufacturing in Europe and secure long-term supply capacity
|
|
08 Feb 2021 |
Sinovac Receives Conditional Marketing Authorization in China for its COVID-19 Vaccine
|
|
08 Feb 2021 |
COVAXX’s COVID-19 Vaccine, UB-612, Induced Neutralizing Antibodies in 100% of Participants During Phase 1 Clinical Trial
|
|
06 Feb 2021 |
Science Advances: Elicio Therapeutics’ SARS-CoV-2 Vaccine Demonstrates T Cell Responses >25 Fold Higher Than Benchmark Vaccines
|
|
06 Feb 2021 |
Sinovac Announces Phase III Results of Its COVID-19 Vaccine
|
|
05 Feb 2021 |
First-in-human clinical trial confirms novel HIV vaccine approach developed by IAVI and Scripps Research
|
|
05 Feb 2021 |
Novavax Announces Start of Rolling Review by Multiple Regulatory Authorities for COVID-19 Vaccine Authorization
|
|
05 Feb 2021 |
Johnson & Johnson Announces Submission of Application to the U.S. FDA for Emergency Use Authorization of its Investigational Single-Shot Janssen COVID-19 Vaccine Candidate
|
|
04 Feb 2021 |
Intrommune Receives IND Clearance From U.S. Food and Drug Administration for INT301
|
|
04 Feb 2021 |
Dynavax and Serum Institute of India Announce First Participant Dosed in a Phase 1 Clinical Trial Evaluating an Improved Tdap Vaccine Adjuvanted with CpG 1018
|
|
03 Feb 2021 |
Vaxart Announces Positive Preliminary Data from Phase 1 Clinical Trial Evaluating Its Oral COVID-19 Tablet Vaccine Candidate
|
|
03 Feb 2021 |
GSK and CureVac to develop next generation mRNA COVID-19 vaccines
|
|
03 Feb 2021 |
COVAXX Announces Initiation of Phase 2 Clinical Trials in Taiwan of UB-612 Vaccine Candidate against COVID-19
|
|
03 Feb 2021 |
COVID-19 Vaccine AstraZeneca confirms 100% protection against severe disease, hospitalisation and death in the primary analysis of Phase III trials
|
|
01 Feb 2021 |
SQZ Biotechnologies Announces FDA Clearance of IND Application to Allow for Clinical Trial with SQZ Activating Antigen Carriers (SQZ AACs) in Patients with HPV+ Tumors
|
|
29 Jan 2021 |
Johnson & Johnson Announces Single-Shot Janssen COVID-19 Vaccine Candidate Met Primary Endpoints in Interim Analysis of its Phase 3 ENSEMBLE Trial
|
|
29 Jan 2021 |
COVID-19 Vaccine AstraZeneca recommended for use in the EU
|
|
29 Jan 2021 |
Novavax COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 Trial
|
|
28 Jan 2021 |
OncoSec Announces First Subjects Dosed in Phase 1 Trial of CORVax12, OncoSec's COVID-19 Vaccine Candidate Combining Interleukin-12 (IL-12) with an Enhanced SARS-CoV-2 Spike Protein
|
|
26 Jan 2021 |
Providence Therapeutics announces first subject has been dosed in COVID-19 vaccine trial
|
|
26 Jan 2021 |
Medigen Vaccine Biologics COVID-19 Vaccine Adjuvanted with Dynavax's CpG 1018 Announces First Participant Dosed in Phase 2 Clinical Trial in Taiwan
|
|
25 Jan 2021 |
BioVaxys Announces Initiation of Cancer Vaccine EU Clinical Program, Completion of BVX-0320 Preclinical Program
|
